Status | Study |
Completed |
Study Name: Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Condition: Gastrointestinal Carcinoid Tumor Islet Cell Tumor Date: 2007-03-27 Interventions: Other: questionnaire administration Proced |
Completed |
Study Name: Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Condition: Neuroendocrine Tumor Islet Cell Tumor Date: 2007-02-09 Interventions: Drug: Sunitinib malate Sunitin |
Terminated |
Study Name: A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Condition: Carcinoma, Islet Cell Carcinoma, Pancreas Date: 2007-01-29 Interventions: Drug: sunitinib malate |
Completed |
Study Name: AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Condition: Gastrointestinal Carcinoid Tumor Islet Cell Tumor Date: 2007-01-25 Interventions: Drug: AMG 706 AMG 706 was admi |
Completed |
Study Name: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Condition: Gastrointestinal Carcinoid Tumor Islet Cell Tumor Date: 2006-12-27 Interventions: Drug: fluorouracil Drug: irinotecan hydroc |
Completed |
Study Name: Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Condition: Islet Cell Carcinoma Neuroendocrine Carcinoma Date: 2006-08-02 Interventions: Drug: Everolimus 10 mg Partici |
Withdrawn |
Study Name: Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Condition: Gastrointestinal Carcinoid Tumor Islet Cell Carcinoma Date: 2005-09-26 Interventions: Drug: octreotide acetate Drug: vatalanib |
Recruiting |
Study Name: Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Condition: Gastrointestinal Carcinoid Tumor Islet Cell Tumor Date: 2005-09-26 Interventions: Biological: bevacizumab 5mg/kg |
Completed |
Study Name: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Condition: Neuroendocrine Carcinoma Islet Cell Carcinoma Date: 2005-06-07 Interventions: Drug: RAD001 Starting dose of |
Completed |
Study Name: Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Condition: Metastatic Gastrointestinal Carcinoid Tumor Pulmonary Carcinoid Tumor Date: 2004-10-06 Interventions: Drug: temsirolimus Given IV |